Market research
4575.TSE CanBas Co., Ltd
TSE JPY Healthcare
Latest close
As of 27 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 15B
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- -0.83
Profile
Company facts
- Exchange
- TSE
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- JP3244570002
- Market cap
- 15B
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- -0.83
About
About CanBas Co., Ltd
CanBas Co., Ltd., a clinical stage biopharmaceutical company, engages in the basic research and clinical development of anti-cancer drugs. The company develops CBP501, a compound which regulates the regulatory function of the protein calmodulin in Phase 2 clinical trials targeting non-small cell lung cancer; and CBS9106 for patients with advanced solid tumors. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan.
Research context
CanBas Co., Ltd appears in PyInvesting’s Tokyo Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 4575.TSE discussion.
5 years, 6 months ago
CanBas Co., Ltd is currently in a long term downtrend where the price is trading 23.0% below its 200 day moving average.
From a valuation standpoint, the stock is 55.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 31.3.
CanBas Co., Ltd's total revenue rose by 0.0% to $28M since the same quarter in the previous year.
Its net income has increased by 21.6% to $-100M since the same quarter in the previous year.
Based on the above factors, CanBas Co., Ltd gets an overall score of 3/5.